Kristen E. Pascal
Regeneron
22 Papers
47 Citations
Kristen E. Pascal is an academic researcher from Regeneron. The author has contributed to research in topics: Antibody & Biology. The author has an hindex of 15, co-authored 19 publications.
Chat about Author
Papers
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more
TL;DR: The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.
Alina Baum,Benjamin O. Fulton,Elzbieta Wloga,Richard Copin,Kristen E. Pascal,Vincenzo Russo,Stephanie Giordano,Kathryn Lanza,Nicole Negron,Min Ni,Yi Wei,Gurinder S. Atwal,Andrew J. Murphy,Neil Stahl,George D. Yancopoulos,Christos A. Kyratsous +15 more
TL;DR: This work investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails.
1.4K
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
Johanna Hansen,Alina Baum,Kristen E. Pascal,Vincenzo Russo,Stephanie Giordano,Elzbieta Wloga,Benjamin O. Fulton,Ying Yan,Katrina Koon,Krunal Patel,Kyung Min Chung,Aynur Hermann,Erica Ullman,Jonathan W. Cruz,Ashique Rafique,Tammy T. Huang,Jeanette L. Fairhurst,Christen Libertiny,Marine Malbec,Wen-Yi Lee,Richard Welsh,Glen Farr,Seth Pennington,Dipali Deshpande,Jemmie Cheng,Anke Watty,Pascal Bouffard,Robert Babb,Natasha Levenkova,Calvin R. Chen,Bojie Zhang,Annabel Romero Hernandez,Kei Saotome,Yi Zhou,Matthew C. Franklin,Sumathi Sivapalasingam,David C. Lye,Stuart Weston,James Logue,Robert Haupt,Matthew B. Frieman,Gang Chen,William C. Olson,Andrew J. Murphy,Neil Stahl,George D. Yancopoulos,Christos A. Kyratsous +46 more
TL;DR: In this article, the authors describe parallel efforts using both humanized mice and convalescent patients to generate antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, which yielded a large collection of fully human antibodies that were characterized for binding, neutralization and three-dimensional structure.
1.3K
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
Leonid Yurkovetskiy,Xue Wang,Kristen E. Pascal,Christopher Tomkins-Tinch,Thomas Nyalile,Yetao Wang,Alina Baum,William E. Diehl,Ann Dauphin,Claudia Carbone,Kristen Veinotte,Shawn B. Egri,Stephen F. Schaffner,Stephen F. Schaffner,Jacob E. Lemieux,James B. Munro,Ashique Rafique,Abhi Barve,Pardis C. Sabeti,Christos A. Kyratsous,Natalya Dudkina,Kuang Shen,Jeremy Luban +22 more
TL;DR: It is shown that D614G was more infectious than the ancestral form on human lung cells, colon cells, and on cells rendered permissive by ectopic expression of human ACE2 or of ACE2 orthologs from various mammals, including Chinese rufous horseshoe bat and Malayan pangolin.
1K
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Ugur Sahin,Alexander Muik,Isabel Vogler,Evelyna Derhovanessian,Lena M. Kranz,Mathias Vormehr,Jasmin Quandt,Nicole Bidmon,Alexander Ulges,Alina Baum,Kristen E. Pascal,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Peter Koch,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Manuel Tonigold,Carsten Boesler,Corinna Rosenbaum,Ludwig Heesen,Marie Cristine Kühnle,Asaf Poran,Jesse Z. Dong,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Tania Palanche,Armin Schultz,Sybille Baumann,Azita J. Mahiny,Gábor Boros,Jonas Reinholz,Gábor Szabó,Katalin Karikó,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Mark Cutler,David A. Cooper,Christos A. Kyratsous,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +48 more
TL;DR: BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavalirus disease-19 (COVID-19)1 as mentioned in this paper.